• Customer Care
  • (888) 123-4567


Rise Therapeutics is recruiting a full-time molecular biologist to lead its synthetic biology initiatives at our Rockville, Maryland laboratory. This position offers a unique opportunity for an entrepreneurial minded scientist to advance the skills and experience necessary for a successful career in the biotechnology industry. The molecular biologist will support research and development strategies that harness new microbiome discoveries to create novel and innovative synthetic biology-based medicines.

Required Qualifications

  • Degree (MS and/or PhD) in the life sciences, biotechnology, biochemistry, microbiology, biomedical engineering, or equivalent
  • Expertise in molecular biology techniques
  • Solid understanding microbiological science
  • Strong knowledge of prokaryotic genetics
  • Understanding of microbial metabolism
  • Familiarity with bacterial genome modification approaches
  • Strong writing skills
  • Effective communication skills with the ability to contribute in a fast-paced environment
  • Strong sense of responsibility for deadlines and data accuracy
  • Rigor and attention to detail including laboratory notebook documentation
  • Comfort with collaboration in a team-based environment

Duties and Responsibilities

  • Lead new drug development strategies for synthetic biology-based cellular medicines
  • Develop and characterize novel microbiome drug candidates
  • Perform analytical testing procedures for product characterization
  • Develop new microbiology genetic modification systems and scientific assessment procedures
  • Analyzing data to identify limitations and bottlenecks in the performance of your microbes and designing strains in silico based on the above
  • Support discovery and development of new functionally-directed bacteria strains
  • Author SOPs, reports, and other controlled documents important for IND filings


  • Support initiatives to develop novel microbiome-associated products
  • Gain experience working in biotech helping to drive new medicines into clinical testing
  • Expand relationships/connections with leading biotechnology researchers


About Rise Therapeutics

Rise Therapeutics is an emerging, privately held company located in Rockville, Maryland which leverages its expertise in synthetic biology and immunological drug development to create novel cellular-based immune therapies. With a strong emphasis on product development and its internal clinical GMP manufacturing infrastructure, Rise is focused on developing immunological-based biological medicines using a unique and proprietary oral biologics delivery platform. Our drug development focus is driven by new microbiome-related discoveries enabling development of targeted, first-in-class immune modulatory drugs for the treatment of inflammation, autoimmunity, cancer, and infection. In the context of its expertise in synthetic biology medicine, proprietary TPX oral drug delivery platform, and clinical GMP manufacturing capabilities, Rise is creating and rapidly advancing life changing cellular-based medicines to the market. For more information, go to www.risetherapeutics.com.  


Please email your CV or resume to: This email address is being protected from spambots. You need JavaScript enabled to view it.

Our News

Biotech company receives follow-on funding to accelerate ongoing clinical development efforts

TEDCO, Maryland’s economic engine for technology companies, announced a recent Seed Funds investment of $200,000 into Rise Therapeutics, a Maryland-based biotechnology company. TEDCO’s Seed Funds invest in early-stage, technology and life sciences companies and provides access to gap financing.

Rockville, Maryland - Rise Therapeutics, a biotech company focused on developing novel immunological-directed synthetic biology-based therapeutics, announced today that it has received funding from the National Institutes of Health (NIH) to develop a novel therapeutic for Acute Respiratory Distress Syndrome (ARDS). The funding will support completion of product validation studies and preparation for clinical development for the program. Rise’s functionally directed immunotherapy engages natural gut microbiome-associated immunological processes with the potential to diminish lung neutrophilia, reduce inflammation, upregulate regulatory T cells, and restore airways epithelial barrier to balance and reset the patient’s immunological repertoire.

Rockville, Maryland, January 31st, 2023 – Rise Therapeutics, a biopharmaceutical company engaged in developing novel oral synthetic biology medicines, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a Phase 1 clinical trial of its lead program candidate, R-3750.